 |
|
| DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES
| |
| | |
|
|
Editors-in-Chief:
Raymond Baker, Eliot Ohlstein
See editorial board for all editors information
Description
The Drug Discovery Today reviews collection provides a resource of
review content aligning the key output of human molecular
medicine with the
specific requirements of the drug discovery process. It is designed to
systematically cover the essential elements
of molecular medicine and drug
discovery, in a manner that has relevance to those actually working on the
discovery and development
of new drugs.This collection will evolve to create
a highly structured database and will act as a one-stop-shop for high quality
content.
What are the biotechnical challenges in ensuring drug action, especially with regard to biopharmaceuticals? Drug Discovery Today:
Therapeutic Strategies discusses the varied strategies used, including stem-cell therapy, vaccination, gene therapy, tissue modelling,
tissue and non-tissue implants and many others.
Other titles in this series include:
Drug Discovery Today: Disease Mechanisms
Drug Discovery Today: Disease Models
Drug Discovery Today: Technologies
There will be four issues each
year.
The Drug Discovery Today reviews collection is only available online.
Ethics in Publishing: General Statement
The Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing.
While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the
paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research
and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers,
iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing
research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with
informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft
a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and
procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the
Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A
conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or
organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the
Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting
a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures
if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the
basis of the declared conflict.
For more information, please refer to:  http://www.elsevier.com/wps/find/authorshome.authors/conflictsofinterest
Bibliographic & ordering information
ISSN: 1740-6773
Imprint: ELSEVIER
Commenced publication 2004
Subscriptions for the year 2008,
Volume 5,
4 issues
Institutional price: Order form
USD 2,366 for all countries except Europe, Japan and Iran
EUR 2,115 for European countries and Iran
JPY 280,800 for Japan
Conditions of sale & ordering procedures, and links to our regional sales offices.
Audience
Anyone working in life science, pharmaceutical or medical research with an interest in the applications directed to the prevention, diagnosis,
treatment or eradication of disease, and basic science researchers, medical researchers, clinicians, lecturers and students. This includes
employees in big and small pharma companies and medium to large biotech companies involved in either developing R&D technologies
or producing a large pipeline of innovative human therapies.
602/188
Last update: 23 Jul 2008
|
|
| |
| | |
|
|
| |
